Figure 6. In vivo activity of cp-Fab/CAR-T based on WT Fab_5.
Three cohorts of NSG mice (n = 5) were inoculated with 1 × 106 IGROV-1/ffluc cells via i.p. injection. After 6 days, 2 × 107 CAR-Ts and WT Fab_5 (10 μg), an equimolar amount of compound 6, or unprogrammed WT Fab (10 μg) were administered by the same route. The mice received a total of one dose of CAR-T and 10 doses of cp-Fab, compound, or Fab daily. (a) Bioluminescence images of all 15 mice were taken from day 6 (before treatment) to day 30 (after treatment) at the indicated time points. (b) Starting on day 6, all 15 mice were imaged and their radiance was recorded (mean ± SD). Significant differences between cohorts treated with WT Fab_5 and WT Fab or compound 6 and WT Fab were calculated using an unpaired two-tailed t-test (*, p < 0.05; **, p < 0.01; ***, p < 0.001). (c) Corresponding Kaplan-Meier survival curves with p-values using a log-rank (Mantel-Cox) test (*, p < 0.05; **, p < 0.01). (d) The weight of all 15 mice was recorded on the indicated days (mean ± SD).